Success rates for US and Canadian anticancer drug development efforts in pediatric oncology.

The proportion of interventions advancing from phase 1 testing to FDA approval was similar to estimates for adult oncology. Our findings highlight the challenges for current paradigms of pediatric anticancer drug development.